Article
Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer.
Thrombosis research - 1 Dec 2023
Aparicio Inmaculada, Iranzo Patricia, Reyes Roxana, Bote Helena, Saigi María, Bringas Marianela, Bosch-Barrera Joaquim, Corral Jesús, Aparisi Francisco, Ruffinelli Jose C, Jiménez Beatriz, Lage Yolanda, López-Castro Rafael, Majem Margarita, Vázquez Sergio, Artal Ángel, Rodríguez-Pérez Ángel, Lázaro-Quintela Martín, Torres José Miguel Sánchez, Reguart Noemí, Cucurull Marc, Gil-Bazo Ignacio, Camps Carlos, Nadal Ernest, Del Barrio Anabel, Garrido Pilar, Dómine Manuel, Álvarez Rosa, Muñoz Andrés J, Calles Antonio
Abstract excerpt
INTRODUCTION: We aimed to determine if advanced BRAF-mutant NSCLC has a higher thromboembolic events (TEE) rate than the expected. METHODS: Between 2008 and 2021, 182 patients with BRAF-mutant advanced NSCLC (BRAF V600E, n = 70; BRAF non-V600E, n = 112) were retrospectively identified from 18 centers in Spain. Patients received chemotherapy (n = 147), immunotherapy (n = 69), targeted therapy (n = 42), and...
Topics
- Humans
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Non-Small-Cell Lung
- Incidence
- Lung Neoplasms
- Mutation
- Proto-Oncogene Proteins B-raf